Article

Oncology's Prior Authorization Problem: Providers Continue to Face Significant Barriers

Prior authorization (PA) requirements continue to be one of the biggest hurdles for oncology providers—impacting access, increasing administrative burdens, and frustrating both patients and physicians. Read our latest analysis to learn why.

Article

Thought Leadership Whitepaper: How Will Medicare Drug Price Negotiations Really Impact Providers?

As manufacturers prepare for Medicare drug price negotiations, a critical question emerges: How will your provider engagement strategy evolve when Maximum Fair Prices (MFP) take effect in 2026?

Article

Meet Cindy: Data Integrity Expert and Pastry Connoisseur

One of Cindy’s favorite parts of working at HMP Market Access Insights is being part of a small, close-knit team. Collaborating with colleagues from different backgrounds has helped her expand her framework for viewing research.

Article

Meet Chris: Payer Oncology Expert and Insight Sleuth

Chris passionately dig deeply into research to uncover nuggets of information that can make a real difference. His favorite part of the job? Interacting with clients and helping them view challenges through a fresh lens.

Article

Meet Dan: Researcher, Dad, and Oncology Report Innovator

At HMP Market Access Insights, we’re lucky to have a team of experts dedicated to uncovering meaningful insights in the oncology space. One of those experts is Dan, whose work is shaping how we approach community oncology research.

Article

3 Ways Manufacturers Can Drive Communication with Oncologists

Through our ongoing research and recent attendance at the Binaytara Foundation’s Hematology Oncology Conference in Sacramento, we've uncovered a persistent challenge: manufacturers are still falling short with coordinated provider engagement strategies.

Article

Leveraging the IDN Dataset: Your Essential Tool for 2025

As IDNs face increasing complexity in oncology management, having a strategic approach backed by actionable insights is critical. Our dataset doesn’t just offer data—it equips your teams with the tools to anticipate challenges and seize opportunities.

Article

Meet Ashu: Organizer & Researcher Extraordinaire; Artist at Heart

Ashu is the glue that keeps our team organized and running smoothly. This year, he’s been particularly fascinated by the growing consolidation among community practices and how it’s reshaping the oncology landscape.

Article

Beyond AMCs: CAR Ts and Bispecifics in Community Oncology

CAR T-cell and BsAb therapies are powerful but largely confined to AMCs, limiting patient access. Our latest report explores how expanding to community oncology could improve access, addressing key clinical, logistical, and financial challenges.

Article

Meet Emma: Research Leader and Master Baker

Not only does Emma have over a decade of experience supporting academic health systems and integrated delivery networks (IDNs), but she’s also the go-to for a delicious apple pie.

Podcast

2024 Rewind: Most Memorable Quotes & Insights

Our team looked back on some of the most thought-provoking insights from conversations with key decision-makers in oncology. In this podcast episode, we explore the challenges and opportunities faced by oncologists, payers, and pathway developers.

Article

Easier Pathway Access, Greater Pathway Usage

Easier access to oncology pathway recommendations encourages oncologists’ usage and considerations of these recommendations. Our new 2024-2025 Oncology Clinical Pathways Impact Report reveals the variability in pathway integration and usage.

Article

Unlocking Oncology Pathway Impact: Beyond Lives Covered to Real Prescribing Influence

As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.

Podcast

Community Oncology Practice Economics - Podcast Part 3 of 3

In the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.

Article

Bispecific Antibodies: A Balancing Act of Promise and Complexity

Bispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.

Podcast

Community Oncology Practice Economics - Podcast Part 2 of 3

In part 2 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the operational realities of oncology practice economics.

Podcast

Community Oncology Practice Economics - Podcast Part 1 of 3

In part 1 of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore the current state of oncology practice economics.

Article

Navigating the 340B Maze Amid the Inflation Reduction Act

As the Inflation Reduction Act (IRA) introduces new Maximum Fair Pricing (MFP) rules, integrated delivery networks (IDNs) and manufacturers will face the complexities of navigating overlapping 340B discounts and MFPs.

Article

Revolutionizing Cancer Care: EOM's Second Wind and its Current Impact on Community Oncology Practices

The second Enhancing Oncology Model (EOM) application cycle closed on September 16, signaling shifts in community oncology. Explore our 2024 Community Oncology Report to understand EOM’s current impact and changes from this round.

Article

Bispecific Therapies in Community Oncology: Bridging Insights from CPC+CBEx and Beyond

Explore key takeaways from CPC+CBEx on bispecific therapies, highlighting collaboration between hospitals and community practices to expand access and tackle financial challenges.

Article

Community Oncology: Awareness v Action in the Face of the IRA

The Inflation Reduction Act (IRA) will significantly impact community oncology practice financials. As we approach this shift, our latest research from the 2024 Community Oncology Report reveals a current gap between awareness and action.

Prior Authorization Requirements Continue to Impact Providers

Welcome to the August 2024 edition of our Monthly Insight Series! This month we are combining insights from 3 of our customer segment reports and reflecting on provider and payer relationships.

Article

Notes From ATOPP: Providing Bispecific Antibody Treatments in Community Oncology

The ATOPP Summit covered a range of cutting-edge topics, including the shift toward administering cellular therapies to patients in community oncology settings.

Article

Vertical Payers: “Highly Integrated” by 2026

Welcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.

Article

Oncology Clinics Frustrated With Manufacturer Engagement Tactics

Welcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.

Article

When Do Payer Pathways Matter?

While provider-initiated oncology clinical pathways are regaining momentum, payer pathways struggle to find a foothold in this space. Still, they can exert impact under certain conditions.

Article

IDNs’ Numerous Strategies and Tools to Manage High-Cost Drugs

Welcome to the May 2024 edition of our Monthly Insight Series. This month we’re exploring the new tools IDNs have deployed to monitor high-cost drugs. This is a preview of findings from our 2024 IDN Oncology Trend Survey, coming at the end of May.

Article

Following the Money: Rx Revenues Underpin Community Oncology Business Models

Welcome to the April 2024 edition of our Monthly Insight Series. This month we’re looking at community oncology practices’ reliance on buy-and-bill drug revenues.

Article

IDN Financial Incentives: Impact on Treatment Prices?

Navigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.

Article

Provider Economics Drive Oncologist Consolidation

Welcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.